Filing Details

Accession Number:
0000899243-22-004665
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-02-03 18:11:27
Reporting Period:
2022-02-01
Accepted Time:
2022-02-03 18:11:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1590750 Viridian Therapeutics Inc. VRDN Services-Medical Laboratories (8071) 471187261
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1730615 Jonathan Violin C/O Viridian Therapeutics, Inc.
221 Crescent Street, Suite 401
Waltham MA 02453
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-02-01 16,751 $19.55 614,154 No 4 S Direct
Common Stock Disposition 2022-02-02 12,340 $18.47 601,814 No 4 S Direct
Common Stock Disposition 2022-02-03 909 $19.16 600,905 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2022-02-02 280,000 $0.00 280,000 $18.51
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
280,000 2032-02-02 No 4 A Direct
Footnotes
  1. This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.90 to $20.23. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.32 to $19.49. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.04 to $19.66. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. The option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.